Filing Analysis
VSee Health, Inc. held its annual meeting of stockholders on August 25, 2026, where shareholders approved a proposal granting the Board authority to execute a reverse stock split with a ratio between 1-for-20 and 1-for-80.
🚩 Red Flags
- Approval of a significant reverse stock split (up to 1-for-80) often indicates a need to boost the share price to meet exchange listing requirements or avoid delisting.
📋 Key Facts
- Annual meeting held on August 25, 2026.
- Quorum was established with 50.65% of total outstanding shares represented.
- Shareholders approved the appointment of WWC, P.C. as independent auditors for fiscal year 2026.
- Shareholders approved the Board's authority to implement a reverse stock split (ratio 1-for-20 to 1-for-80) by the second anniversary of the Record Date.
- Kevin Lowdermilk and Colin O’Sullivan were elected to the Board of Directors.
VSee Health, Inc. has received a formal delisting determination from Nasdaq because its stock price fell below $0.10 for ten consecutive trading days. Trading of common stock and warrants is scheduled to be suspended on August 6, 2026.
🚩 Red Flags
- Immediate delisting/trading suspension scheduled for August 6, 2026.
- Extreme share price depreciation (trading at or below $0.10).
- Failure to regain compliance during multiple extension periods.
- Potential loss of liquidity and exchange prestige via transition to OTC markets.
📋 Key Facts
- Nasdaq issued a Staff Delisting Determination under Rule 5810 due to the security's closing bid price being $0.10 or less for ten consecutive trading days as of July 29, 2026.
- Trading of common stock and warrants is set to be suspended at the opening of business on August 6, 2026.
- The company was previously granted an extension to regain compliance with the $1.00 Bid Price Rule until September 21, 2026, but failed to meet the sub-$0.10 threshold trigger.
- A Form 25-NSE will be filed to remove securities from listing and registration on Nasdaq.
- The company has until August 6, 2026, at 4:00 p.m. ET to request a hearing before the Nasdaq Hearings Panel, which requires a $20,000 non-refundable fee.
VSee Health, Inc. entered into a $336,000 unsecured convertible promissory note agreement with Labrys on June 30, 2026. The financing includes aggressive conversion terms and a right for the lender to seize up to 50% of certain cash proceeds.
🚩 Red Flags
- Highly dilutive conversion feature: Conversion price is a 25% discount to the 10-day low closing bid.
- Aggressive 'cash sweep' provision: Lender can demand up to 50% of incoming cash proceeds (including customer payments and equity raises) for debt repayment.
- Unsecured status: The $336,000 note is unsecured, providing no collateral protection for the lender.
- Potential death spiral characteristics: The floating conversion price based on a discount to recent trading prices can lead to significant dilution.
📋 Key Facts
- Entered into a securities purchase agreement (Labrys SPA) on June 30, 2026.
- Issued an unsecured convertible promissory note with an aggregate principal amount of $336,000 (includes $36,000 original issue discount).
- Note carries a one-time interest charge of 12% guaranteed and earned as of the issue date.
- Maturity date is June 30, 2027.
- Conversion price is set at 75% of the lowest closing bid price during the 10 trading days prior to a conversion notice.
- Lender has the right to require immediate repayment of up to 50% of certain cash proceeds (from customers, equity/debt issuance, asset sales, etc.) upon receipt.
VSee Health, Inc. entered into a Settlement Agreement with ADI Funding LLC and M2B Funding Corp to resolve defaults related to an existing secured promissory note and equity line of credit (ELOC). The settlement involves significant cash payments, the issuance of new promissory notes, and the issuance of 1 million total restricted shares to settle outstanding disputes.
🚩 Red Flags
- Default/Settlement context: The agreement resolves defaults triggered by failure to file registration statements and 8-Ks.
- Heavy dilution risk: Issuance of 1,000,000 restricted shares as part of a settlement.
- Aggressive conversion terms: Settlement notes allow conversion at a significant discount (75% of lowest 20-day VWAP).
- Cash drain: Immediate $50,000 cash requirement and potential $500/day penalties.
- Debt acceleration risk: Failure to comply with settlement terms triggers immediate acceleration of all obligations.
📋 Key Facts
- Settlement Agreement executed on July 21, 2026, with ADI Funding LLC and M2B Funding Corp.
- Company must repay $271,739.13 Existing Note within 90 days or upon receipt of any financing transaction proceeds.
- 50% of gross proceeds from future financing transactions (excluding ELOC) must be applied to the Existing Note until repaid.
- Immediate cash payment of $50,000 required to ADI; failure to pay results in a $500/day late charge.
- Issuance of $50,000 promissory note to ADI and $125,000 promissory note to M2B (both 6-month maturity, 18% retroactive interest if defaulted).
- Issuance of 500,000 restricted shares to ADI and 500,000 restricted shares to M2B.
- Settlement notes include conversion rights at 75% of the lowest 20-day VWAP.
VSee Health, Inc. announced the ratification of its 2026 Annual Meeting of Stockholders scheduled for August 25, 2026. The company also established July 6, 2026, as the record date for determining shareholder eligibility to vote.
📋 Key Facts
- 2026 Annual Meeting of Stockholders is set for August 25, 2026.
- The record date for stockholder eligibility was July 6, 2026.
- Stockholder proposals must be submitted by the close of business on July 17, 2026.
- The company is an emerging growth company.
VSee Health, Inc. entered into two separate unsecured convertible note agreements with institutional investors (ClearThink and Vanquish) in June 2026, totaling approximately $575,550 in principal.
🚩 Red Flags
- Death Spiral Provisions: Both notes feature conversion prices based on a significant discount to the market price (85% and 75%), which typically leads to massive dilution.
- No Reverse Split Protection: The Vanquish Note explicitly states the conversion price will not be adjusted by a reverse stock split, making it extremely punitive for existing shareholders in a declining stock scenario.
- Extremely Low Floor Price: The ClearThink note has a $0.01 floor price, allowing for massive share issuance if the stock price collapses.
- High Immediate Interest/Discount: One-time interest charges of 10% and 12% applied at issuance increase the effective cost of capital significantly.
📋 Key Facts
- Entered ClearThink SPA on June 22, 2026: $280,000 unsecured convertible note due June 22, 2027.
- ClearThink Note conversion price: 85% of the lowest closing price over 10 trading days prior to notice; fixed floor price of $0.01.
- Entered Vanquish SPA on June 18, 2026: $295,550 unsecured convertible note due April 15, 2027.
- Vanquish Note conversion price: 75% of the lowest closing bid price over 10 trading days prior to notice; no adjustment for reverse stock splits.
- Both notes include a beneficial ownership limitation of 4.99%.
- Both notes are subject to immediate interest charges (10% for ClearThink, 12% for Vanquish) applied on issuance.
VSee Health, Inc. received a notice of default from ADI Funding, LLC regarding an 8% original issue discount secured promissory note totaling $271,739.13. The default stems from the company's alleged failure to file a resale registration statement (Form S-1), a Form 8-K, and transfer agent instructions by June 11, 2026.
🚩 Red Flags
- Event of Default on secured promissory note.
- Potential acceleration of debt and enforcement of collateral rights.
- Compliance failures regarding SEC filings (Form S-1 and 8-K) which can trigger broader regulatory scrutiny or delisting risks.
📋 Key Facts
- Notice of Event of Default received on June 12, 2026, from ADI Funding, LLC.
- The underlying debt is an 8% original issue discount secured promissory note with a principal amount of $271,739.13 (including $21,739.13 OID).
- Alleged defaults include failure to file Form S-1 for resale registration, failure to file required Form 8-K, and failure to issue transfer agent instructions.
- The Company has ten (10) Trading Days from the occurrence of the Event of Default to cure the default.
- If not cured, the Holder may accelerate debt and enforce collateral rights.
VSee Health, Inc. entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. on June 2, 2026, providing the company access to up to $10 million in equity financing through 2029.
🚩 Red Flags
- The SEPA is a 'death spiral' style financing mechanism where shares are issued at a discount (97% of VWAP), which typically leads to significant dilution and downward pressure on the stock price.
- The company is an 'Emerging Growth Company', which often correlates with higher volatility and less stringent reporting requirements.
📋 Key Facts
- Commitment Amount: Up to $10 million in Common Stock purchases by YA II PN, LTD.
- Pricing: Shares will be issued at 97% of the lowest daily VWAP during a 3-day pricing period.
- Fees: $25,000 structuring fee and 532,481 commitment shares (approx. 1% of commitment amount).
- Exchange Cap: Maximum issuance of 9,715,140 shares (approx. 19.99% of outstanding shares) without stockholder approval.
- Ownership Limit: Investor cannot exceed 4.99% beneficial ownership of outstanding shares.
- Duration: Agreement expires June 2, 2029, or upon full utilization of the $10 million.
VSee Health entered into a Securities Purchase Agreement on June 8, 2026, issuing a secured promissory note to an institutional investor (ADI Funding LLC) for a principal amount of $271,739.13.
🚩 Red Flags
- Extremely high interest rate (18% per annum) suggests high risk or desperation for liquidity
- The loan is secured by company assets, increasing the risk of asset seizure upon default
- The presence of an Original Issue Discount (OID) is often a sign of predatory or high-cost short-term financing
- Multiple 8-K items (1.01, 2.03, 3.02) in a single filing
📋 Key Facts
- Principal amount of Promissory Note: $271,739.13
- Includes an original issue discount (OID) of $21,739.13
- Interest rate: 18% per annum
- Maturity date: December 8, 2026
- Prepayment fee: 10% of the amount being prepaid
- The note is secured by certain assets of the company via a Security Agreement
- Repayment is mandatory within two business days of receiving proceeds from an equity line of credit financing arrangement with the same holder
VSee Health entered into a Stock Purchase Agreement with its co-CEO and Chairman, Milton Chen, to sell all equity of its wholly-owned subsidiary, VSee Lab, to him. In exchange, Mr. Chen transferred 2,870,069 shares of VSee Health common stock back to the company and resigned from his executive and board positions.
🚩 Red Flags
- Related-party transaction: The asset sale and stock transfer involved the company's own co-CEO and Chairman.
- Multiple 8-K items in a single filing (1.01, 2.01, 3.02, 5.02).
- Significant divestiture of a wholly-owned subsidiary (VSee Lab) to an insider.
- Sudden resignation of the Chairman and co-CEO.
📋 Key Facts
- Transaction Date: May 31, 2026
- Asset Disposition: Company sold all equity securities of VSee Lab, Inc. (a wholly-owned subsidiary) to Milton Chen.
- Consideration: Mr. Chen transferred 2,870,069 shares of VSee Health common stock to the Company.
- Management Change: Milton Chen resigned as co-CEO and Chairman of the Board effective May 31, 2026.
- New Leadership: Dr. Imoigele Aisiku appointed as sole CEO and Chairman of the Board.
- Liability Split: Mr. Chen is responsible for VSee Lab indebtedness not paid at closing, while the Company retains liabilities occurring prior to the closing date (excluding certain sales/use taxes).
VSee Health, Inc. stockholders approved a private placement proposal at a special meeting held on March 2, 2026. The approval allows for the issuance of up to 19,672,130 shares of common stock to certain warrant holders, satisfying Nasdaq Listing Rule 5635(d).
🚩 Red Flags
- Significant potential dilution: The approved issuance of 19,672,130 shares represents approximately 45.5% of the 43,244,355 shares outstanding as of the record date.
📋 Key Facts
- Special Meeting of stockholders held on March 2, 2026.
- As of the February 2, 2026 record date, there were 43,244,355 shares of common stock outstanding.
- Stockholders approved the issuance of up to 19,672,130 shares of common stock to warrant holders.
- The Private Placement Proposal passed with 14,109,726 votes FOR and 7,698,963 votes AGAINST.
- The Adjournment Proposal was withdrawn as the primary proposal was successfully adopted.
VSee Health disclosed two interrelated agreements with GoMyRx, Inc., a digital prescription fulfillment platform: a Managed Services Agreement (MSA) for cost-plus-10% services dated December 26, 2025, and a Stock Purchase Agreement dated January 16, 2026, under which VSEE will acquire 10% of GMRx for $2.0 million from Go Biz Holdings, LLC. The filing was made approximately 55 days after the earliest reported event, well beyond the standard 4-business-day 8-K deadline.
🚩 Red Flags
- Significantly late filing: earliest event December 26, 2025 but 8-K not filed until February 19, 2026 (~55 days), far exceeding the 4-business-day requirement
- $2.0 million equity investment in a private company with no disclosed financials for GMRx — shareholders cannot assess whether the implied $20M valuation is reasonable
- Secondary share purchase from Go Biz Holdings means the $2M capital goes to the selling entity, not to GMRx for growth — raises questions about who benefits
- Intertwined service and equity relationship: VSEE is simultaneously a service provider to and equity investor in GMRx, creating potential conflicts of interest
- GMRx can terminate the MSA with only 20 days notice, an asymmetrically unfavorable term for VSEE
- Restricted shares with no clear liquidity path — VSEE's $2M investment is effectively locked up in a private, illiquid position
- No disclosure of any relationship between Go Biz Holdings and VSEE insiders or directors — the filing is silent on whether this is a related-party transaction
📋 Key Facts
- VSEE entered a Managed Services Agreement with GoMyRx, Inc. on December 26, 2025, to provide platform administration, customer/user support, vendor coordination, and reporting/governance services
- MSA billing is at actual cost plus 10% margin, invoiced monthly — a modest markup
- MSA expires December 26, 2027 with optional 6-month extensions; GMRx can terminate with only 20 days written notice
- On January 16, 2026, VSEE agreed to purchase $2.0 million of GMRx common stock from Go Biz Holdings, LLC, representing 10% ownership in GMRx (implying a $20M valuation for GMRx)
- Shares purchased are restricted securities under Section 4(a)(2) / Rule 506 of Regulation D — cannot be freely sold
- GoMyRx is described as 'an affiliate company of the GoMyDocs healthcare ecosystem'
- The $2M purchase is a secondary transaction (from Go Biz Holdings), meaning proceeds go to the seller, not to GMRx for business operations
- Filing signed by Co-CEO Imoigele Aisiku on February 19, 2026 — 55 days after the December 26 MSA event
VSee Health, Inc. reported the results of its annual meeting of stockholders held on December 30, 2025. The meeting resulted in the election of two directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on December 30, 2025.
- Dr. Milton Chen and Dr. Imoigele Aisiku were elected to the Board of Directors (Class I).
- WWC, P.C. was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- The VSee Health Inc. 2025 Equity Incentive Plan was approved by stockholders.
- Quorum was met with 35.74% of total outstanding shares represented at the meeting.
VSee Health, Inc. has amended its bylaws to significantly reduce the quorum requirement for stockholder meetings from a standard majority to one-third (33.33%) of voting power. This change is applied retroactively to the 2025 Annual Meeting scheduled for December 30, 2025.
🚩 Red Flags
- Reduction in quorum requirements can be used by management to push through controversial measures with minimal shareholder participation.
- Retroactive application of bylaws changes is an aggressive governance tactic often viewed negatively by institutional investors.
📋 Key Facts
- Board approved amendment to Bylaws on December 17, 2025.
- Quorum requirement reduced to one-third (33.33%) of voting power.
- The quorum change is applied retroactively to the 2025 Annual Meeting of Stockholders.
- Annual Meeting scheduled for December 30, 2025, via live webcast.
VSee Health, Inc. has postponed its 2025 Annual Meeting of Stockholders from December 15, 2025, to December 30, 2025. The postponement is due to the company's anticipation that it will not have a sufficient number of shares present or represented by proxy to constitute a quorum.
🚩 Red Flags
- Quorum Risk: The inability to meet a quorum is a significant governance red flag, often indicating low shareholder engagement or potential issues with the voting process/shareholder base.
- Governance Instability: Postponing an annual meeting due to lack of participation can signal underlying investor apathy or dissatisfaction.
📋 Key Facts
- Original meeting date: Monday, December 15, 2025, at 2:30 p.m. ET.
- New meeting date: Tuesday, December 30, 2025, at 2:30 p.m. ET.
- Reason for postponement: Anticipated failure to reach a quorum of stockholders.
- Record date remains November 20, 2025.
- The meeting will be conducted via live webcast.
VSEE Health, Inc. filed an amendment to its 8-K to provide a pro forma balance sheet demonstrating compliance with Nasdaq's minimum stockholders' equity requirement. The company achieved a pro forma total stockholders' equity of $9.5 million as of December 1, 2025, following various debt and payable conversions.
🚩 Red Flags
- History of stockholders' deficit ($18,488 as of Dec 31, 2024).
- Delisting risk/Nasdaq non-compliance history.
- Significant dilution likely occurred through the conversion of notes and payables into common/preferred shares to fix the balance sheet.
📋 Key Facts
- Company was non-compliant with Nasdaq Listing Rule 5550(b)(1) due to equity falling below the $2.5M minimum.
- As of Dec 31, 2024, the company reported a stockholders' deficit of $18,488.
- The Nasdaq Hearings Panel granted an exception to complete a compliance plan by Dec 1, 2025.
- Compliance was achieved via 'Transactions' including warrant exercises, conversion of convertible notes/preferred shares, and exchange of payables for equity.
- Pro forma stockholders' equity as of Dec 1, 2025, is $9.5 million (previously estimated at $13.2M in the original filing).
- The company maintains its listing on the Nasdaq Capital Market subject to demonstrating long-term compliance.
VSee Health, Inc. has filed a Certificate of Designation for the issuance of 2,000 shares of Series B Convertible Preferred Stock. This new class of stock ranks senior to common stock and carries significant conversion rights.
🚩 Red Flags
- Significant potential dilution: The conversion price of $0.65 is substantially lower than the warrant strike price of $11.50 mentioned in the header, suggesting heavy downward pressure on common stock value.
- Liquidation preference: Series B holders are entitled to receive stated value plus accrued dividends before common stockholders in a liquidation scenario.
📋 Key Facts
- Issuance of 2,000 shares of Series B Preferred Stock effective December 5, 2025.
- Each share has a stated value of $1,000.
- Series B ranks senior to Common Stock and Junior Securities; parity with Series A.
- Conversion price is set at $0.65 per share (as-if-converted basis).
- Conversion right can be exercised once Investor Gross Proceeds from the sale of all Investor Shares is less than $2.3 million.
- Includes a 9.99% beneficial ownership limitation on conversion to prevent excessive dilution/control.
VSEE Health, Inc. has announced it believes it has achieved compliance with Nasdaq's minimum stockholders' equity rule through a series of debt-for-equity and warrant exercise transactions. The company is filing this 8-K to satisfy the Nasdaq Panel's requirement to demonstrate compliance by December 1, 2025.
🚩 Red Flags
- History of negative stockholders' equity (deficit of $18,488 as of year-end 2024).
- Delisting risk was imminent; the company was under a deadline to prove compliance by Dec 1, 2025.
- Heavy reliance on dilutive transactions (note conversions and payable exchanges) to fix the balance sheet.
📋 Key Facts
- Nasdaq notified the company on September 2, 2025, of non-compliance with Rule 5550(b)(1) due to stockholders' equity falling below $2.5M.
- The company reported a stockholders' deficit of $18,488 as of December 31, 2024.
- Compliance was sought via 'Transactions' including warrant exercises, conversion of convertible notes and preferred shares, and exchange of payables for equity.
- Pro forma balance sheet (as of Dec 31, 2025) shows total stockholders' equity of $13.2 million, significantly above the $2.5M requirement.
- The compliance plan required disclosure by December 1, 2025.
VSee Health, Inc. entered into a $6 million private placement agreement with an institutional investor to issue common stock and warrants at a significant discount. The deal includes heavy dilution through pre-funded warrants and accompanying warrants that could potentially double the share count.
🚩 Red Flags
- Significant potential dilution: The accompanying warrants represent nearly double the number of shares being sold in the primary offering.
- Low-cost financing: The $0.61 exercise price for warrants is likely significantly below current market value, facilitating massive future dilution.
- Restrictive covenants: 90-day prohibition on issuing other equity or entering variable rate transactions following registration effectiveness.
- Requirement for stockholder approval: Failure to obtain approval could trigger ongoing meeting requirements every 90 days.
📋 Key Facts
- Gross proceeds of approximately $6 million from a single institutional/accredited investor.
- Issuance of 9,836,065 shares (or pre-funded warrants) at $0.61 per share.
- Issuance of accompanying warrants to purchase up to 19,672,130 additional shares of Common Stock.
- Warrants have an exercise price of $0.61 and expire in five years.
- The company must obtain stockholder approval for the issuance of the warrants/shares.
- Placement agent (A.G.P.) to receive a 7% cash fee plus expenses ($50,000 + $10,000).
- Expected closing date is on or about December 1, 2025.
VSee Health, Inc. entered into a convertible note purchase agreement with an institutional investor for $217,391 in principal plus 50,000 shares of common stock. The deal includes high-interest terms and significant dilution potential via a low conversion price.
🚩 Red Flags
- High-interest rate (18% p.a.) indicative of distressed financing needs.
- Significant dilution risk due to a conversion price ($0.48) that may be substantially lower than current market value.
- Death Spiral feature: Investor can convert at 75% of the effective price in a Qualified Financing.
- Asset-backed debt: The note is secured by all company assets, increasing lender priority over equity holders.
- Prepayment penalty: 10% fee required to prepay the Note.
📋 Key Facts
- Date of Agreement: October 29, 2025
- Principal Amount: $217,391 convertible promissory note
- Equity Component: 50,000 shares of common stock issued as part of the purchase price
- Aggregate Purchase Price: $201,000
- Interest Rate: 18% per annum (first 8 months interest is guaranteed and accrues immediately)
- Conversion Price: $0.48 per share (effective January 29, 2026)
- Maturity Date: October 29, 2026
- Security Interest: Note is secured by a security interest in all of the Company's assets.
VSee Health, Inc. entered into two significant financing agreements on November 13, 2025: an exchange of a $611,878 promissory note for common stock and the establishment of a $25 million Equity Line of Credit (ELOC). The ELOC allows an institutional investor to purchase shares at a discount to VWAP, which is highly dilutive.
🚩 Red Flags
- Highly dilutive financing: The $25M ELOC allows an investor to purchase shares at a significant discount (4-6%) to market price.
- Debt conversion: Converting existing debt into equity via a Section 3(a)(9) exchange often indicates liquidity constraints and immediate dilution for current shareholders.
- Death Spiral potential: The pricing mechanism in the ELOC (linked to VWAP with a floor/discount) is characteristic of 'death spiral' financing that can lead to massive share issuance if the stock price declines.
📋 Key Facts
- Entered into an Exchange Agreement to settle a promissory note with a current balance of $611,878.22 in exchange for 941,352 shares of common stock.
- Executed a Directed Stock Purchase Agreement (DSPA) establishing a $25,000,000 Equity Line of Credit (ELOC).
- The ELOC has a 36-month term and can be terminated by the Company at any time.
- Regular purchase price for the ELOC is 96% of the lowest VWAP over 10 trading days (or 94% if price falls below $1.00).
- The Investor in the ELOC is restricted from owning more than 9.99% of issued and outstanding stock at any one time.
- Company may not sell more than 19.9% of its total outstanding shares under the DSPA terms.
VSee Health, Inc. entered into a warrant exchange agreement with an institutional investor to convert outstanding warrants into common stock. The deal involves both cash exercises and non-cash exchanges of warrants for equity.
🚩 Red Flags
- Significant dilution: The exchange of 2.25M warrants for 2.175M shares represents a substantial issuance of common stock.
- Warrant price ($11.50) vs current market context: While the strike is $11.50, the non-cash exchange component suggests an attempt to clean up the cap table or satisfy debt/obligations via equity rather than cash.
📋 Key Facts
- Date of Agreement: October 29, 2025
- Holder agreed to exercise ~130,000 warrants for cash at $11.50 per share.
- Holder will exchange 2,250,000 warrants for 2,175,000 shares of common stock (non-cash exchange).
- The company is prohibited from issuing new equity, effecting a reverse stock split, or filing a registration statement for the next ten days.
VSee Health, Inc. announced the scheduling of its 2025 Annual Meeting of Stockholders and established a record date for voting eligibility.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for December 15, 2025.
- The record date for determining stockholder eligibility to vote at the meeting is November 20, 2025.
- Stockholder proposals must be submitted by the close of business on November 7, 2025, to be included in proxy materials.
VSee Health, Inc. entered into an amendment to its existing senior secured convertible promissory note, significantly revising the conversion price of the debt.
🚩 Red Flags
- Significant downward revision of conversion price: The amendment sets the conversion price at $0.75, which likely represents a substantial discount to current market value (implied by the existence of warrants with an $11.50 strike price).
- Potential for massive dilution: A low conversion price on a senior secured note allows the holder to acquire a large percentage of equity upon conversion.
- Debt restructuring/renegotiation: Repeated amendments to debt terms (Sept 2024, March 2025, and now Oct 2025) suggest ongoing liquidity or solvency management issues.
📋 Key Facts
- Amendment No. 1 to a senior secured convertible promissory note was executed on October 21, 2025.
- The original principal amount of the Note is $2,222,222.
- The Amendment revises the 'Conversion Price' to be equal to $0.75 per share.
- The note was originally issued on September 30, 2024, and previously amended on March 20, 2025.
VSee Health, Inc. entered into a $133,333 secured note purchase agreement with an institutional investor on October 20, 2025, and simultaneously terminated a previous Equity Purchase Agreement (ELOC). The new debt is fully secured by the assets of the Company and its subsidiaries.
🚩 Red Flags
- High-interest default penalty (up to 24% per annum).
- Restrictive covenants: Prohibits the company from entering into variable rate transactions or any exchange transactions involving securities.
- Significant asset encumbrance: The note is fully secured by assets of the Company and its subsidiaries, adding to existing security agreements with Dominion Capital LLC.
- Termination of an Equity Purchase Agreement (ELOC) often suggests a shift in financing strategy or inability to utilize previous equity-based funding.
📋 Key Facts
- Issued a secured note for $133,333.33 principal amount at a purchase price of $120,000.
- Note bears 5% annual interest and matures on May 20, 2026.
- Default penalty includes an interest rate hike to the lesser of 24% per annum or the legal maximum.
- The Note is fully secured by assets of the Company and its subsidiaries via amendments to existing security agreements with Dominion Capital LLC.
- Terminated a November 21, 2023 Equity Purchase Agreement (ELOC) on October 18, 2025.
- Agreement includes restrictive covenants prohibiting variable rate transactions and exchange transactions involving company debt/securities.
VSee Health, Inc. has dismissed its independent auditor, WithumSmith+Brown, PC, and appointed WWC, P.C. as its new accounting firm. The dismissal follows a period where the previous auditor issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language in prior audits.
- Presence of material weaknesses in internal controls (as noted in 2024 10-K).
- The company is an emerging growth company, which often correlates with higher volatility and different reporting requirements.
📋 Key Facts
- Dismissal of WithumSmith+Brown, PC (Withum) effective September 15, 2025.
- Appointment of WWC, P.C. effective September 18, 2025, to audit FY2025 and review interim periods for 2025.
- The previous auditor's report for the fiscal year ended December 31, 2024, included an explanatory paragraph regarding 'substantial doubt about the Company’s ability to continue as a going concern'.
- Material weaknesses were identified in the company's Annual Report on Form 10-K for the year ended December 31, 2024.
- The company states the dismissal was not due to any violation of law or fraud.
VSee Health, Inc. entered into a note purchase agreement for a $133,333 secured note at a discount to par ($120,000), alongside amendments to existing security agreements with Dominion Capital LLC.
🚩 Red Flags
- Debt financing at a discount (issued $133k for $120k) suggests urgent need for liquidity.
- Restrictive covenants: Prohibits variable rate transactions and exchange transactions involving company debt/securities.
- Most-favored-nation clause: Requires providing the investor with any more favorable terms granted to future lenders.
- High default interest penalty (up to 24% per annum).
- The note is fully secured by assets of the Company and its subsidiaries.
📋 Key Facts
- Entered into Note Purchase Agreement on October 9, 2025.
- Issued a secured note with aggregate principal amount of $133,333.33 for a purchase price of $120,000.
- Note bears an interest rate of 5% per annum and matures on May 8, 2026.
- Default interest rate is the lesser of 24% or the maximum legal rate.
- The Note is non-convertible.
- Amendment to existing Security Agreements with Dominion Capital LLC to include this new Note as collateral.
VSee Health, Inc. received a Nasdaq Staff Deficiency Letter due to its common stock bid price falling below the $1.00 minimum requirement for 30 consecutive business days. The company is also currently non-compliant with Nasdaq rules regarding timely SEC filings and minimum stockholders' equity.
🚩 Red Flags
- Delisting notice (bid price deficiency)
- Failure to file timely quarterly reports (Form 10-Q)
- Stockholders' equity below minimum requirements
- Potential for a reverse stock split to regain compliance
- Risk of limited liquidity and adverse price impact if delisted
📋 Key Facts
- Received Nasdaq Staff Deficiency Letter on September 24, 2025, due to bid price falling below $1.00 (Nasdaq Rule 5550(a)(2)).
- The company has an initial 180-day period to regain compliance, expiring March 23, 2026.
- To regain compliance via a second 180-day period, the company may need to effect a reverse stock split.
- Currently non-compliant with Nasdaq Rule 5250(c)(1) for failing to file Form 10-Qs for periods ended March 31, 2025, and June 30, 2025.
- Currently non-compliant with Nasdaq Rule 5550(b)(1) as stockholders' equity fell below $2.5 million as of December 31, 2024.
VSee Health, Inc. is facing imminent delisting from Nasdaq due to multiple compliance failures, including late periodic filings and a violation of the Equity Rule (stockholders' equity below $2.5M). A hearing with the Nasdaq Hearings Panel is scheduled for September 9, 2025.
🚩 Red Flags
- Imminent delisting from a major exchange (Nasdaq).
- Multiple failures to file required periodic reports (10-K and multiple 10-Qs).
- Violation of the Equity Rule due to insufficient stockholders' equity.
- Expected transition to OTC Markets, which typically results in significantly lower liquidity and higher volatility.
📋 Key Facts
- Nasdaq denied the Company's request to continue listing due to failure to timely file Form 10-K (FY ended Dec 31, 2024) and multiple Form 10-Qs.
- The Company is in violation of Nasdaq Listing Rule 5550(b)(1) because stockholders' equity fell below the $2.5 million minimum requirement.
- As of December 31, 2024, the Company reported a stockholders' deficit of $18,488.
- Trading in common stock (VSEE) and public warrants (VSEEW) is expected to suspend on August 28, 2025, pending an appeal decision.
- A hearing before the Nasdaq Hearings Panel is scheduled for September 9, 2025.
VSee Health, Inc. has announced that it will restate its prior financial statements for multiple periods due to significant accounting errors identified during the preparation of its 2024 Form 10-K. The company also admitted to material weaknesses in its internal control over financial reporting and ineffective disclosure controls.
🚩 Red Flags
- Restatement of multiple years/quarters of financial data
- Admission of material weaknesses in internal controls over financial reporting
- Ineffective disclosure controls and procedures
- Complex errors stemming from a recent Business Combination (SPAC merger context)
📋 Key Facts
- The company is restating financial statements for VSee Lab, Inc. covering periods as early as March 31, 2023, through September 30, 2024.
- Errors include failure to accrue sales/use taxes, incorrect revenue cutoffs, and improper recognition of accrued expenses related to the Business Combination (Digital Health Acquisition Corp. and iDoc).
- Management concluded that material weaknesses exist in internal control over financial reporting.
- The errors involve complex issues including convertible note interest, equity line of credit commitment fees, and acquisition-related accounting for non-controlling interests.
VSee Health, Inc. faces imminent delisting from Nasdaq due to repeated failures to file required periodic reports (10-K for FY2024 and 10-Qs for Q1 and Q2 2025). Trading in common stock and warrants is scheduled to be suspended on August 28, 2025, pending an appeal hearing on September 9, 2025.
🚩 Red Flags
- Imminent delisting from a major exchange (Nasdaq)
- Chronic failure to meet SEC filing deadlines (multiple 10-K and 10-Q delays)
- Suspension of trading for both common stock and public warrants
- High uncertainty regarding the outcome of the September 9 hearing
📋 Key Facts
- Nasdaq denied the Company's request to continue listing due to non-compliance with Rule 5250(c)(1).
- The company failed to file its Annual Report (Form 10-K) for the fiscal year ended December 31, 2024.
- The company failed to file Quarterly Reports (Form 10-Q) for periods ended March 31, 2025, and June 30, 2025.
- Trading suspension is set for August 28, 2025, unless an extension is granted by the Nasdaq Hearings Panel.
- A hearing before the Nasdaq Hearings Panel is scheduled for September 9, 2025.
- Upon delisting, shares and warrants are expected to trade on the OTC Markets system under symbols VSEE and VSEEW.
VSee Health, Inc. has been notified by Nasdaq that its request to continue listing is denied due to failure to file timely annual (10-K) and quarterly (10-Q) reports. Trading on the Nasdaq is scheduled to be suspended on August 14, 2025, with an expected move to the OTC Markets.
🚩 Red Flags
- Delisting notice from Nasdaq (Item 3.01).
- Failure to file mandatory periodic reports (10-K and 10-Q) for over a year/multiple quarters.
- Suspension of trading on a major exchange (Nasdaq) leading to OTC transition.
- High uncertainty regarding the success of the appeal process.
📋 Key Facts
- Nasdaq Staff denied the Company's request to continue listing on the exchange.
- Trading of common stock (VSEE) and warrants (VSEEW) will be suspended on Nasdaq at the open of trading on August 14, 2025.
- The company expects its securities to begin trading on the OTC Markets system starting August 14, 2025.
- Delisting is a result of failure to file Form 10-K for fiscal year ended Dec 31, 2024, and Form 10-Q for period ended March 31, 2025.
- The Company intends to appeal the determination to the Nasdaq Listing and Hearing Review Council.
VSee Health, Inc. received a notice from Nasdaq stating it is non-compliant with listing rules due to its failure to timely file its Form 10-Q for the period ended March 31, 2025. The company has 60 days to submit a compliance plan and may receive up to an 180-day extension if accepted.
🚩 Red Flags
- Delisting notice received from Nasdaq.
- Failure to meet mandatory SEC filing deadlines (Form 10-Q).
- Uncertainty regarding the ability to submit a compliance plan or file required reports within the granted window.
📋 Key Facts
- Received Nasdaq notice on May 23, 2025, regarding non-compliance with Nasdaq Listing Rule 5250(c)(1).
- The deficiency is due to the failure to timely file the Form 10-Q for the period ended March 31, 2025.
- The company has 60 calendar days from the notice date to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an exception of up to 180 days from the Form 10-Q's due date (potentially until October 13, 2025).
- The notice has no immediate effect on the listing status of Common Stock (VSEE) or Public Warrants (VSEEW).
VSee Health, Inc. received a notice from Nasdaq for non-compliance with listing rules due to failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The delay is attributed to complexities in compiling audited financial statements following its de-SPAC merger in June 2024.
🚩 Red Flags
- Delisting notice received for failure to file timely periodic reports.
- Ongoing inability to meet financial reporting deadlines despite a previous Form 12b-25 extension.
- Complexity in auditing post-merger financials suggests potential internal control or accounting transition issues.
📋 Key Facts
- Received Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) on April 25, 2025.
- Failure to file Form 10-K for the fiscal year ended December 31, 2024.
- The company has 60 calendar days from the notice to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an exception of up to 180 days (until approximately October 13, 2025).
- The delay stems from difficulties compiling audited financials post-de-SPAC merger.
VSee Health, Inc. entered into multiple debt and equity amendments on March 20, 2025, involving the issuance of senior secured notes and convertible notes to institutional investors. The company is actively restructuring existing obligations and taking on new high-interest, secured debt to raise capital.
🚩 Red Flags
- High-interest debt: The Second Note carries an 18% coupon, jumping to 28% upon default.
- Dilutive financing: Issuance of common stock and convertible notes to satisfy debt obligations/commitments.
- Complex capital structure: Multiple layers of secured and subordinated notes (including a $2.5M note from June 2024) create significant liquidation preference risk for common shareholders.
- Liquidity pressure: The company is actively amending agreements and issuing new secured notes, suggesting immediate cash needs.
📋 Key Facts
- Issued a $555,555.56 senior secured note to an existing investor (SPA Amendment) with 5% interest maturing Nov 1, 2025; includes 100,000 shares of common stock as commitment shares.
- Issued a $108,695.65 secured convertible note to a Second Investor with 18% interest maturing Dec 20, 2025; conversion price is the greater of $2.00 or a floating floor based on recent Nasdaq closing prices.
- Amended an existing Equity Purchase Agreement (from Nov 2023) to set a new floor price of $1.25 per share.
- The Second Note features a default interest rate hike up to 28% per annum.
VSee Health, Inc. announced a contract renewal valued at approximately $870,000 with a nationwide mental and behavioral healthcare provider.
📋 Key Facts
- Contract renewal value: approximately $870,000.
- Counterparty: A nationwide provider of mental and behavioral healthcare services.
- Announcement date: January 27, 2025.
- The filing is under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for liability purposes.
VSee Health, Inc. announced the execution of new contracts with multiple medical technology solution companies. The total value of these newly secured contracts is approximately $935,000.
📋 Key Facts
- Date of event: January 21, 2025
- Total contract value: Approximately $935,000
- Counterparties: Several medical technology solution companies
- Filing date: January 27, 2025
VSee Health, Inc. announced two significant contract wins via press releases under Item 7.01, including a $6 million multi-year government contract and a $160,000 health system contract in Florida.
🚩 Red Flags
- Information provided under Item 7.01 is not 'filed' for purposes of Section 18 liability, meaning the company has limited legal recourse/liability regarding the accuracy of these specific press releases compared to standard filed items.
📋 Key Facts
- Awarded a multi-year government contract with $6M allocated for the first year (announced Jan 13, 2025).
- Awarded a contract with a prominent Florida health system valued at approximately $160,000 (announced Jan 10, 2025).
- The company is classified as an emerging growth company.
VSee Health, Inc. announced two significant business developments involving teleradiology services contracts. The company secured a national group purchasing agreement with Premier, Inc. and a contract with a major US post-acute care hospital system.
📋 Key Facts
- Awarded a national group purchasing agreement for teleradiology services with Premier, Inc. on December 18, 2024.
- Awarded a teleradiology contract with one of the largest post-acute care hospital systems in the United States on December 19, 2024.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for liability purposes.
VSee Health, Inc. announced a strategic partnership with Tele911, an ER diversion solution provider, via a press release dated December 16, 2024.
📋 Key Facts
- Partnership announced with Tele911 on December 16, 2024.
- Tele911 is described as a leading ER diversion solution provider.
- The filing was submitted under Item 7.01 (Regulation FD Disclosure).
VSee Health, Inc. announced a strategic partnership with AbundaBox to launch 'AbundaLife™', a health record management platform.
📋 Key Facts
- Strategic partnership announced on December 6, 2024, with AbundaBox.
- The partnership focuses on the launch of the AbundaLife™ health record management platform.
- Filing includes an exhibit (99.1) containing the full press release regarding the partnership.
VSee Health, Inc. announced a strategic partnership with The TeleDentists to provide integrated virtual oral health compliance services via the PointClickCare Marketplace.
📋 Key Facts
- Partnership announced on November 21, 2024.
- The collaboration involves integration into the PointClickCare Marketplace.
- The partnership aims to offer the first and only virtual oral health compliance solution through this specific marketplace.
VSee Health, Inc. issued a press release regarding the expansion of its 'Project VITAL Africa' telehealth pilots in Cameroon. The initiative involves partnerships with Health Tech Without Borders and iDocta to strengthen health systems through sustainable training and technology.
📋 Key Facts
- Expansion of Project VITAL Africa telehealth pilots announced on November 19, 2024.
- Partnerships include Health Tech Without Borders and iDocta.
- Focus is on strengthening health systems and promoting equitable health in Cameroon.
- The initiative stems from a commitment made at the Clinton Global Initiative 2023 Annual Meeting.
VSee Health, Inc. filed an 8-K to furnish its quarterly financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of financial results (Item 2.02).
- Reporting period covers the three and nine months ended September 30, 2024.
- The company is an 'emerging growth company' as defined by the SEC.
VSee Health, Inc. announced a strategic partnership with BabyLiveAdvice to provide an innovative maternal care platform designed to address staffing and service gaps for hospitals, payers, and FQHCs.
📋 Key Facts
- Partnership announced on October 29, 2024, between VSee Health, Inc. and BabyLiveAdvice.
- The collaboration focuses on a maternal care model powered by the Company's platform.
- Target customers include hospitals, payers, and Federally Qualified Health Centers (FQHCs).
VSee Health, Inc. issued a press release regarding the launch of a new telehealth program focused on obesity management through GLP-1 prescription medicines. This is a regulatory disclosure under Item 7.01 and does not constitute material non-public information being released for the first time.
📋 Key Facts
- Launched a specialized telehealth program targeting obesity and associated health risks.
- Program integrates GLP-1 prescription medicines into existing service offerings.
- The announcement was made via press release on October 21, 2024.
VSee Health, Inc. issued a press release regarding a telehealth demonstration initiative in collaboration with the Kwajalein Atoll Local Government and Kwajalein Atoll Sustainability Laboratory.
📋 Key Facts
- The company successfully demonstrated a telehealth initiative aimed at improving healthcare access for Marshallese veterans and residents of the Kwajalein Atoll.
- Collaboration involves the Kwajalein Atoll Local Government and Kwajalein Atoll Sustainability Laboratory.
- Filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for liability purposes.
The company issued an 8-K to furnish press releases regarding upcoming speaking engagements for Co-CEO Milton Chen at two industry events in October 2024.
📋 Key Facts
- Co-CEO Milton Chen is scheduled to speak at the STAR-TIDES Fireside Chat on October 22, 2024.
- The topic of the STAR-TIDES chat is 'Why Your Digital Health Transformation Will Be Slow and Likely Hacked'.
- Milton Chen will be a keynote speaker at iA-Med 2024 on October 16, 2024, focusing on AI advancements in healthcare.
VSee Health, Inc. entered into a securities purchase agreement on September 30, 2024, to issue $2.22 million in senior secured convertible notes to an institutional investor. The deal includes warrants and commitment shares, and is heavily collateralized by substantially all company assets.
🚩 Red Flags
- High-risk financing structure involving senior secured convertible notes
- Lien on substantially all company assets including core IP/patents
- Significant potential dilution from 740,741 warrants and 100,000 commitment shares
- Default interest rate of 24% per annum is highly punitive
- The security interest covers the company's primary value drivers (IP/Patents)
📋 Key Facts
- Total principal amount of Note: $2,222,222.22
- Interest rate: 10% per annum; default interest rate up to 24% per annum
- Maturity date: March 30, 2026
- Warrants issued: 740,741 warrants with an exercise price of $2.25 per share (5-year term)
- Commitment shares: 100,000 shares of common stock to the Investor
- Collateral: Substantially all assets, including intellectual property, trademarks, and patent rights
- Lock-up agreement signed by directors and officers until the Note is no longer outstanding
VSee Health, Inc. filed an 8-K to furnish its quarterly financial results for the three and six months ended June 30, 2024.
📋 Key Facts
- Report date: September 23, 2024
- Reporting period: Three and six months ended June 30, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
- Company is an emerging growth company.
VSee Health, Inc. received a notice from Nasdaq for non-compliance with listing rules due to failure to file its Quarterly Report (Form 10-Q) for the period ended June 30, 2024. The delay is attributed to ongoing valuation complexities related to the recent de-SPAC acquisition of iDoc Virtual Telehealth Solutions, Inc.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules.
- Failure to file periodic financial reports (Form 10-Q).
- Complexity in accounting/valuations following a de-SPAC transaction, which often leads to prolonged reporting delays.
📋 Key Facts
- Received Nasdaq notice on September 6, 2024, for violation of Nasdaq Listing Rule 5250(c)(1).
- The company failed to file its Form 10-Q for the quarter ended June 30, 2024.
- The company has until November 5, 2024, to submit a plan to regain compliance.
- Delays are caused by completing valuations related to the acquisition of iDoc Virtual Telehealth Solutions, Inc. (de-SPAC transaction from June 2024).
- Nasdaq may grant up to 180 days from the Form 10-K due date (potentially until February 18, 2025) to regain compliance if a plan is accepted.
VSee Health, Inc. filed an 8-K to announce the launch of its Aimee telehealth service in Wichita, Kansas, through a partnership with Stand Together.
📋 Key Facts
- Launched 'Aimee' telehealth service in Wichita, Kansas on August 6, 2024.
- The expansion is being conducted in partnership with an entity named 'Stand Together'.
- The filing was made under Item 7.01 (Regulation FD Disclosure) as a press release announcement.
VSee Health, Inc. announced a strategic partnership with Ava Robotics to develop telepresence solutions for the inpatient intensive care market using VSee-powered robots.
📋 Key Facts
- Partnered with Ava Robotics on August 1, 2024.
- Objective: Develop telepresence solutions for the inpatient intensive care market.
- Product focus: A VSee-powered Ava robot to allow remote personalized care by healthcare providers.
VSee Health, Inc. announced a partnership with SkywardRx to provide telehealth and billing services to various client segments including nonprofit, hospital, and Fortune 20 corporate entities.
📋 Key Facts
- Partnership announced on July 24, 2024.
- Partner is SkywardRx, a digital healthcare services and consulting firm.
- Scope of partnership includes telehealth and billing services.
- Target client base for the partnership includes nonprofit organizations, hospitals, and Fortune 20 corporate clients.
VSee Health, Inc. expanded its Board of Directors from five to seven members, appointing Cydonii V. Fairfax and David L. Wickersham as new Class III directors effective July 17, 2024.
🚩 Red Flags
- Related-party transaction: David L. Wickersham's previous debt settlement involved the issuance of 114,000 shares of company common stock.
📋 Key Facts
- Board size increased from five to seven members.
- Cydonii V. Fairfax appointed to the Audit Committee and Chair of the Nominating Committee.
- David L. Wickersham appointed as Chair of the Compensation Committee.
- Ms. Fairfax is currently EVP and General Counsel at Metropolitan Transit Authority of Harris County, Texas.
- Mr. Wickersham previously settled a $224,000 secured convertible promissory note via 114,000 shares of common stock issued in March 2024.
VSee Health, Inc. announced on July 9, 2024, that it has commenced providing outpatient specialty medical services for the United States Federal Bureau of Prisons.
📋 Key Facts
- The company has begun providing outpatient specialty medical services to the U.S. Federal Bureau of Prisons.
- Announcement made via press release on July 9, 2024.
- The filing is under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for liability purposes.
VSee Health, Inc. (formerly Digital Health Acquisition Corp.) has amended a $3 million convertible promissory note and issued a new $500,000 senior unsecured note payable in common stock to satisfy commitment fees related to its business combination.
🚩 Red Flags
- Use of convertible promissory notes and senior unsecured notes payable in stock is a common method for micro-cap companies to fund operations, often leading to significant future dilution.
- The extension of the maturity date on the $3M note suggests a need for more time to meet repayment obligations or manage cash flow.
- Guaranteed interest payments regardless of early redemption increase the cost of capital for the company.
📋 Key Facts
- Amended the 'Quantum Note' ($3M principal) to extend maturity from June 25, 2025, to June 30, 2026.
- The amended Quantum Note guarantees eighteen months of interest regardless of early redemption/payoff.
- Issued a $500,000 Equity Purchase Commitment Note on July 2, 2024, payable only in common stock at an initial price of $10 per share.
- The company officially updated its Code of Ethics to reflect the name change from Digital Health Acquisition Corp. to VSee Health, Inc.
VSee Health, Inc. (formerly Digital Health Acquisition Corp.) consummated its business combination on June 24, 2024, merging with VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc. The transaction resulted in a significant restructuring of equity and the issuance of various preferred stock and common shares to lenders and former stockholders.
🚩 Red Flags
- Significant debt-to-equity conversion: Large amounts of common stock and preferred stock issued to lenders as part of the closing.
- Complex capital structure involving multiple series of preferred stock (Series A) and convertible notes.
- Potential dilution for public shareholders due to massive issuance of shares to former entities and lenders.
📋 Key Facts
- Business combination closed on June 24, 2024, involving VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc.
- Company name changed from Digital Health Acquisition Corp. (DHAC) to VSee Health, Inc.
- Total Common Stock outstanding post-closing: approximately 14,692,820 shares.
- VSee Lab stockholders received ~0.40 shares of Common Stock per share held.
- iDoc stockholders received ~994.38 shares of Common Stock per share held.
- Issued 892,500 shares of Common Stock to lenders following conversion of debt via A&R Loan Conversion SPAs.
- The company issued a $3,000,000 'Quantum Note' (7% OID convertible promissory note) on June 25, 2024.
Digital Health Acquisition Corp. (DHAC) successfully held a Special Meeting of Stockholders on June 7, 2024, where shareholders approved the Business Combination Proposal to merge with VSee Health, Inc. The meeting also resulted in the approval of several charter amendments and the election of five directors.
🚩 Red Flags
- The filing includes multiple approvals for various financing proposals (Quantum Financing, Equity Financing, A.G.P. Financing, Loan Conversions, and Bridge Financing) that involve the potential issuance of more than 20% of common stock, which often leads to significant shareholder dilution.
📋 Key Facts
- The Business Combination Proposal was approved by a significant majority (3,233,699 votes FOR).
- Shareholders approved changing the company name from Digital Health Acquisition Corp. to 'VSee Health, Inc.'
- All five director nominees (Milton Chen, Imoigele Aisiku, Kevin Lowdermilk, Colin O’Sullivan, and Scott Metzger) were elected.
- The meeting achieved a quorum with 3,233,699 shares represented via live webcast or proxy out of 3,603,966 total shares entitled to vote.
- No shares of Common Stock were tendered for redemption in connection with the shareholders' vote.
Digital Health Acquisition Corp. has extended its deadline to complete a business combination from May 8, 2024, to August 8, 2024. This represents the third of four possible three-month extensions allowed under the company's governing documents.
🚩 Red Flags
- Repeated extensions suggest difficulty in finalizing a target acquisition or securing funding for the deal.
- The company is approaching its final possible extension period, creating an imminent deadline risk if no merger occurs by November 2024.
📋 Key Facts
- Extension date moved from May 8, 2024, to August 8, 2024.
- This is the third extension granted via a shareholder vote/governing document provision.
- The company has one remaining three-month extension available (the fourth and final one).
- Company operates as a SPAC (Special Purpose Acquisition Company) listed on Nasdaq under ticker VSEE.
Digital Health Acquisition Corp. has entered into multiple amendments to extend the termination dates for its business combination with VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc., as well as extending the maturity dates on existing debt notes.
🚩 Red Flags
- Repeated extensions of business combination deadlines suggest delays in closing the SPAC merger.
- Extension of debt maturity dates (Bridge Notes and Extension Note) to match the merger deadline indicates potential liquidity pressure or reliance on the merger to satisfy obligations.
📋 Key Facts
- Second Amendment to Business Combination Agreement extends the transaction termination date from March 31, 2024, to June 30, 2024.
- Bridge Letter Agreement extends the termination/closing date of the Bridge Notes (totaling $166,667) to June 30, 2024.
- Extension Letter Agreement amends the maturity date of a $300,000 Extension Note from May 5, 2024, to June 30, 2024.
- The company is an emerging growth company.
Digital Health Acquisition Corp. (a SPAC) has entered into a First Amendment to its Third Amended and Restated Business Combination Agreement with VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc. The amendment involves the assumption and conversion of various debts from the target companies into DHAC common stock upon closing.
🚩 Red Flags
- Debt Assumption: The SPAC is assuming significant debt from the target companies ($1.2M+ identified) to facilitate the merger, which will result in equity dilution for existing shareholders.
- Complexity: Multiple amendments and restatements of business combination agreements suggest ongoing negotiations or restructuring of deal terms.
📋 Key Facts
- Date of filing: February 13, 2024.
- The amendment is a 'First Amendment to Third Amended and Restated Business Combination Agreement'.
- DHAC will assume $600,000 of VSee's indebtedness, to be converted into DHAC common stock post-closing.
- DHAC will assume $600,000 of iDoc's indebtedness, subject to registration rights agreements and filing of a registration statement post-closing.
- Additional unspecified indebtedness owned by iDoc will also be assumed and converted into common stock upon execution of registration rights agreements.
Digital Health Acquisition Corp. has extended its deadline to complete a business combination from February 8, 2024, to May 8, 2024. This represents the second of four possible three-month extensions allowed under the company's governing documents.
🚩 Red Flags
- SPAC deadline extension: The company has not yet completed its target merger, indicating ongoing search or negotiation difficulties.
📋 Key Facts
- Extension date: From February 8, 2024, to May 8, 2024.
- This is the second of four permitted three-month extensions.
- The purpose of the extension is to provide additional time to complete a business combination.